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Abstract  
BACKGROUND: The main attribute of asthma is inflammation, which leads to airway remodelling, 
bronchial hyper-reactivity and reversible or partly reversible airway obstruction. According to GINA, 
asthma is a chronic inflammatory disorder of the airways in which many cells play a role, in 
particular, mast cells, eosinophils (Eo), and T lymphocytes. Many cells and mediators take part in 
creating the asthmatic inflammatory reaction, but eosinophils play a central role.  
AIM: The aim of this study was to show the values of biological inflammatory markers (IL-5, Eo, and 
ECP) during treatment with ICS by non-invasive methods. 
MATERIAL AND METHODS: This study includes 30 patients of the Pulmonology and Allergology 
Clinic, Skopje, with confirmed asthma, treated with ICS. In all of the patients, we followed Eo count, 
ECP and IL-5 in peripheral blood at the beginning of the study, after 2 and six months treatment. 
Following the parameters during treatment with ICS we registered changes in all of the tested 
parameters.  
RESULTS: Our results show high level of the tested biomarkers at the beginning of the study, IL-5 
in all patients (100%), Eosinophils in 80%, and ECP in 90% of the asthmatics. Following the 
parameters during treatment with ICS we registered changes in all of the tested parameters. 
CONCLUSIONS: Our conclusion is that the ICS objectively suppress the inflammatory reaction in 
asthma and the biologic markers (IL-5, Eo and ECP), which we have followed, can measure the 
accomplished effect. They could be used in everyday practice, not only as diagnostic parameters 
but also as valid therapeutic guides in the treatment of asthma. 
 
 
Introduction 
 
Asthma is one of the most common chronic 
diseases all over the world, resulting from a state of 
persistent sub-acute inflammation of the airways. 
Asthma is a chronic disease defined by three features: 
inflammation, which leads to airway remodelling, 
bronchial hyper-reactivity and reversible or partly 
reversible airway obstruction. It is known that the 
basis of the pathogenesis of asthma lays chronic 
inflammation. According to GINA, asthma is a chronic 
inflammatory disorder of the airways in which many 
cells play a role, in particular, mast cells, eosinophils 
(Eo), and T lymphocytes (GINA) [1]. Many cells and 
mediators take part in creating the asthmatic 
inflammatory reaction, but eosinophils play a central 
role.  
The immune response is stimulated by T 
lymphocytes by the release of Th2 type cytokines, 
such as IL-3, IL-4, IL-5, and GM-CSF. IL-5 is the 
primary interleukin involved in the production, 
differentiation, maturation, and activation of Eo. It 
takes an important place in the allergic inflammation 
by promoting the chemotaxis, activation and survival 
of Eo and their apoptosis. Il-5 increases the number 
and activity of Eo. Their number in the bone marrow, 
peripheral blood and tracheobronchial mucosa 
increases. Eosinophils are very potent cells. They can 
generate more than 28 newly synthesised cytokines, 
chemokines and growth factors, which are capable of 
modulating the immune response
 
[2]. They contain 
four basic proteins which degranulate during the 
asthmatic reaction: major basic protein (MBP), 
eosinophil cationic protein (ECP), eosinophil 
peroxidase (EPO) and the eosinophil neurotoxin 
(EDN), which damage the bronchial mucosa and 
increase the airway hyper-reactivity [3-5]. With the 
degranulation of Eo, other mediators are released as 
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well, such as LTC4, LTD4, LTE4, and PAF, which 
influence the contractility of airway smooth muscle 
and the permeability of the vessels. Eo are also 
responsible for the local control of the asthmatic 
reaction because they release active biological 
substances which inactivate mediators released by 
mast cells [3, 6].  
Many studies show the correlation between 
the severity of asthma and the number and activity of 
Eo [7, 8]. 
 Up to this date, the most efficient anti-
inflammatory medications in the treatment of bronchial 
asthma are inhaled corticosteroids
 
[9, 10]. Although 
they were introduced in the treatment of asthma more 
than 40 years ago; they still are the first line treatment 
for most patients with asthma
 
[11, 12]. Corticosteroids 
affect almost all cells which take part in the 
inflammatory process in asthma. Laitinen [13] shows a 
decrease in the total cell count in the mucosa of 
asthmatics treated with BDP for three months. 
 Corticosteroids cause a decrease of the Eo 
count [14] and consecutive improvement of asthma 
symptoms. They inhibit the synthesis of IL-4 and IL-5, 
which influence Eo survival and decrease the release 
of cellular mediators and basic protein molecules [15, 
16]. Inhaled corticosteroids decrease the release of 
GM-CSF, which leads to a decrease in the number of 
low-density Eo, meaning inhibition of cytokine 
production. They also influence the apoptosis of Eo. 
Inhaled corticosteroids inhibit the late asthmatic 
reaction within hours of the first application, while 
continuous treatment for at least 4-6 weeks is 
necessary for suppression of the early asthmatic 
reaction. We have followed the anti-inflammatory 
response to ICS by following the serum levels of IL-5 
and ECP and the total Eo count in peripheral blood.  
 The aim of this study was to show the values 
of biological inflammatory markers (IL-5, Eo, and 
ECP) during treatment with ICS by non-invasive 
methods.  
 
 
Material and Methods 
 
 The study was performed at the Pulmonology 
and Allergy Clinic, The Institute for Biochemistry and 
Institute for Immunology, at the Medical Faculty in 
Skopje. We included 30 patients with severe asthma, 
22 (73.33%) female and 8 (26.66%) male, age 18-65 
years. The average age was 35.30  9.65 years. The 
patients were treated with spray Beclomethasone 
dipropionate a 250 g in doses from 1000 to 2000 
g/per day. 
  In each subject the following investigations 
were undertaken at the beginning of the study, after 
two months and at the end of the sixth month of 
continuous treatment: 
 Interleukins: (IL-5) in peripheral blood, by the 
standard methodology of the Institute of 
Biochemistry (ELISA System with appropriate 
antibodies for the IL-5 was used. Referent 
values: 0 pg/ml for IL-5). 
 Total Eo counts and ECP in peripheral blood. 
(Pharmacia CAP System for determination of 
serum ECP was used. Referent values: Eo = 
120-240 x 10
6
/l, ECP < 11.3 mg/l). 
The data were statistically analysed by 
“STATISTICA for Windows", version 4.5, from 1993. 
The changes of the evaluated parameters were tested 
with ANOVA. Values for p < 0.05 were considered 
statistically significant. 
 
 
Results 
 
At the beginning of the study in all 30 (100 
percent) of the patients the serum level of IL-5 was 
increased (44.94  28.87 pg/ml). After two months of 
treatment, the values decreased to 37.44 pg/ml. 
During the 6-months follow-up the average value of 
IL-5 decreased from 44.94  28.87 to 30.44  18.05 
pg/ml (p = 0.000044), but still remained high above 
the referent values (0 pg/ml). 
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Figure 1: Serum level of the IL-5 during six months treatment 
 
In 24 (80%) of the subjects, we found high 
levels of peripheral blood Eo at the beginning of the 
study. The total Eo count was found to be from 150 to 
390 x 10
6
/l; average value was 292.66  67.05 x 10
6
/l. 
After two months, this number decreased to 270  
59.71 x 10
6
/l and at six months it was 224.33  59.17 
x 10
6
/l. 
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Figure 2: Total Eo count in peripheral blood during six months 
treatment 
In 27 (90%) of the subjects we found 
increased levels of serum ECP, before treatment. 
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Values ranged from 4.9 to 42.1 mg/l, average value 
was 22.92  10.08 mg/l. At two months these values 
decreased to 19.36  8.59 mg/l. After six months of 
treatment, the ECP values in peripheral blood were 
from 7 to 30.4 mg/l. Average value decreased from 
22.92  10.08 to 14.47  6.22 mg/l. 
22.92
19.36
14.47
0
5
10
15
20
25
0 period 2 months 6 months
ECP  
Figure 3: Level of the ECP during six months treatment 
 
 
Discussion 
 
Our results are similar to those found in the 
literature [17, 18]. The positive therapeutic effect of 
the inhaled corticosteroids in asthma is promoted by 
induction of apoptotic cellular death of Eo. This 
mechanism can explain the clinical efficiency of 
corticosteroids in the control of asthma symptoms and 
the prevention of exacerbations. Corticosteroids 
markedly decrease the Eo count as well as their 
mediators, by reducing the production of Eo in the 
bone marrow and by their influence on apoptosis.  
The new studies suggest that the efficiency of 
ICS in the reduction of airway hyperreactivity and 
asthma symptoms depends on the increased number 
of Eo in the airways before beginning of treatment 
[19]. A group of Japanese authors used serum ECP 
and the total Eo count as leading markers for step 
down of treatment with ICS. They recommend that the 
serum levels of ECP can be a very sensitive marker 
for determination of the exact time for stepping down 
the treatment [20]. 
The anti-inflammatory effect of corticosteroids 
on Eo is mostly accomplished through reduction of the 
number of IL-5 producing T-cells [21]. Corticosteroids 
inhibit the production of cytokines [22]. A group of 
Swedish authors refer about decrement of the 
expression of IL-5 receptor on Eo during treatment 
with ICS [23]. Numerous studies confirm the reduction 
of Th2 cytokines influenced by aortic therapy [24-27].  
In our study, we found a decrease in the 
serum levels of IL-5 during treatment with ICS, which 
is consistent with the data from the literature.  
The aim of every form of anti-asthmatic 
treatment is to prevent and suppress the inflammation 
of the airways. Still, objective parameters are 
necessary to evaluate the effects of the chosen 
treatment. The markers that we have evaluated 
correlate significantly with the severity of inflammation 
and the effects of the applied therapy. The follow-up 
of these markers in peripheral blood (although less 
sensitive than in bronchoalveolar lavage of bronchial 
mucosa) has an advantage of being non-invasive and 
therefore repeatable as many times as necessary. 
The possibility to determine and follow markers of 
inflammation should be a stimulus for each doctor to 
measure the effects of prescribed treatment or to 
choose the effective therapeutic measures. 
The results of our study show that the ICS 
objectively suppress the inflammatory reaction in 
asthma and the biologic markers (IL-5, Eo and ECP), 
which we have followed, can measure the 
accomplished effect. They could be used in everyday 
practice, not only as diagnostic parameters but also 
as valid therapeutic guides in the treatment of asthma  
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